| Literature DB >> 27246369 |
Yoshiko Atsuta1, Akihiro Hirakawa2, Hideki Nakasone3, Saiko Kurosawa4, Kumi Oshima5, Rika Sakai6, Kazuteru Ohashi7, Satoshi Takahashi8, Takehiko Mori9, Yukiyasu Ozawa10, Takahiro Fukuda4, Heiwa Kanamori11, Yasuo Morishima12, Koji Kato13, Hiromasa Yabe14, Hisashi Sakamaki7, Shuichi Taniguchi15, Takuya Yamashita4.
Abstract
We sought to assess the late mortality risks and causes of death among long-term survivors of allogeneic hematopoietic stem cell transplantation (HCT). The cases of 11,047 relapse-free survivors of a first HCT at least 2 years after HCT were analyzed. Standardized mortality ratios (SMR) were calculated and specific causes of death were compared with those of the Japanese population. Among relapse-free survivors at 2 years, overall survival percentages at 10 and 15 years were 87% and 83%, respectively. The overall risk of mortality was significantly higher compared with that of the general population. The risk of mortality was significantly higher from infection (SMR = 57.0), new hematologic malignancies (SMR = 2.2), other new malignancies (SMR = 3.0), respiratory causes (SMR = 109.3), gastrointestinal causes (SMR = 3.8), liver dysfunction (SMR = 6.1), genitourinary dysfunction (SMR = 17.6), and external or accidental causes (SMR = 2.3). The overall annual mortality rate showed a steep decrease from 2 to 5 years after HCT; however, the decrease rate slowed after 10 years but was still higher than that of the general population at 20 years after HCT. SMRs in the earlier period of 2 to 4 years after HCT and 5 years or longer after HCT were 16.1 and 7.4, respectively. Long-term survivors after allogeneic HCT are at higher risk of mortality from various causes other than the underlying disease that led to HCT. Screening and preventive measures should be given a central role in reducing the morbidity and mortality of HCT recipients on long-term follow-up.Entities:
Keywords: Causes of death; Late effects; Late mortality
Mesh:
Year: 2016 PMID: 27246369 DOI: 10.1016/j.bbmt.2016.05.019
Source DB: PubMed Journal: Biol Blood Marrow Transplant ISSN: 1083-8791 Impact factor: 5.742